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Abstract
Introduction: To close gaps in HIV prevention and care, knowledge about locations and populations most affected by HIV is
essential. Here, we provide subnational and sub-population estimates of three key HIV epidemiological indicators, which have
been unavailable for most settings.
Methods: We used surveillance data on newly diagnosed HIV cases from 2004 to 2014 and back-calculation modelling to
estimate in France, at national and subnational levels, by exposure group and country of birth: the numbers of new HIV infec-
tions, the times to diagnosis, the numbers of undiagnosed HIV infections. The denominators used for rate calculations at
national and subnational levels were based on population size (aged 18 to 64) estimates produced by the French National
Institute of Statistics and Economic Studies and the latest national surveys on sexual behaviour and drug use.
Results: We estimated that, in 2014, national HIV incidence was 0.17& (95% confidence intervals (CI): 0.16 to 0.18) or 6607
(95% CI: 6057 to 7196) adults, undiagnosed HIV prevalence was 0.64& (95% CI: 0.57 to 0.70) or 24,197 (95% CI: 22,296 to
25,944) adults and median time to diagnosis over the 2011 to 2014 period was 3.3 years (interquartile range: 1.2 to 5.7).
Three mainland regions, including the Paris region, out of the 27 French regions accounted for 56% of the total number of
new and undiagnosed infections. Incidence and undiagnosed prevalence rates were 2- to 10-fold higher than the national rates
in three overseas regions and in the Paris region (p-values < 0.001). Rates of incidence and undiagnosed prevalence were
higher than the national rates for the following populations (p-values < 0.001): born-abroad men who have sex with men
(MSM) (respectively, 108- and 78-fold), French-born MSM (62- and 44-fold), born-abroad persons who inject drugs (14- and
18-fold), sub-Saharan African-born heterosexuals (women 15- and 15-fold, men 11- and 13-fold). Importantly, affected popula-
tions varied from one region to another, and in regions apparently less impacted by HIV, some populations could be as
impacted as those living in most impacted regions.
Conclusions: In France, some regions and populations have been most impacted by HIV. Subnational and sub-population esti-
mates of key indicators are not only essential to adapt, design implement and evaluate tailored HIV interventions in France,
but also elsewhere where similar heterogeneity is likely to exist.
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1 | INTRODUCTION
Over the past two decades, remarkable progress has been
achieved in the fight against HIV. The life expectancy of people
living with HIV has dramatically increased since effective
combination antiretroviral treatment (cART) has been available
[1] and continues to improve [2]. Additionally, effective cART, by
reducing the HIV viral load in body fluids to undetectable levels,
prevents onward HIV transmission [3]. Other new prevention
tools, such as Pre-Exposure Prophylaxis (PrEP), that is the use
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of antiretroviral drugs by HIV-negative individuals, have also
shown high effectiveness [4,5]. These advances in HIV treat-
ment and prevention have the potential to dramatically reduce
the number of new HIV infections and could open a new path
towards the end of AIDS epidemic. This prompted the Joint UN
Program on HIV/AIDS (UNAIDS) to launch the ambitious 90-
90-90 target [6], calling for 90% of people living with HIV to
know their HIV status, 90% of them to be on cART and 90% of
them to have achieved viral suppression. However, to reach this
target by 2020, and eventually end the AIDS epidemic, it will
require ensuring rapid and early access to cART as well as
extending tailored prevention services.
In most settings affected by HIV, including high-income
countries, late cART initiation remains common [7-12]. Cur-
rent major obstacles to early access to cART are undiagnosed
and late-diagnosed HIV infections [11-13]. Undiagnosed and
late-diagnosed individuals are at risk of HIV/AIDS-related
morbidity and mortality [14,15], and transmitting HIV [16,17]
because of delayed cART initiation. Ensuring early access to
cART will hence require shrinking the time interval from infec-
tion to HIV diagnosis, by raising awareness about the issue of
undiagnosed and late-diagnosed HIV infections among the civil
society and implementing relevant testing programmes, to
increase uptake of HIV testing among people who may have
undiagnosed HIV and/or be at risk of being diagnosed late.
This necessitates having a comprehensive understanding of
the populations affected by undiagnosed and late-diagnosed
HIV infections as well as whether these populations change
from one location to another. Likewise, extending prevention
services requires identifying the populations at risk of HIV
acquisition in each geographic area, and providing them with
prevention tools tailored to their needs [18].
Some efforts have been undertaken to describe the HIV
epidemics at a finer scale. Most studies focused on the geo-
graphic analysis and mapping of the HIV prevalence [19-22]
and HIV diagnoses [23,24]. Similar efforts to produce subna-
tional and sub-population estimates of HIV incidence, time
from infection to diagnosis and the undiagnosed population,
which are the key epidemiological indicators to guide and eval-
uate HIV prevention and testing programmes, remained to be
investigated in most settings; only the US Centers for Disease
Control and Prevention has recently generated estimates for
HIV incidence and undiagnosed prevalence at the state-level
[22]. More importantly, determining, within a country, whether
and how the populations affected by HIV differ from one geo-
graphic area to another remained to be done.
In this study, we provide a geographical and sub-population
analysis of three key epidemiological indicators: HIV incidence,
distribution of times from HIV infection to diagnosis and
prevalence of undiagnosed HIV infections, and a description of
the populations affected by HIV according to the geographical
area. To conduct this analysis, we used national surveillance
data on newly diagnosed HIV cases in France [23] and a, pre-
viously developed, statistical model [25,26].
2 | METHODS
2.1 | Data source
In France, like in many high-income countries, routine HIV
surveillance is based on case reporting of all new HIV
diagnoses, and conducted by Sante publique France, the
French national public health agency. It was implemented in
March 2003 [27]. Data on new HIV diagnoses include date of
diagnosis, demographic information (sex and country of birth),
HIV exposure group, clinical status at diagnosis (primary HIV
infection (PHI), asymptomatic, symptomatic without AIDS or
AIDS) and region of residence. Reported cases are adjusted
for delay in reporting, under-reporting and missing data [28].
2.2 | HIV incidence and distribution of time from
infection to HIV diagnosis
To estimate HIV incidence and the distribution of time from
infection diagnosis, we used a back-calculation model and data
on newly diagnosed HIV cases. The model has been described
elsewhere [25] and is detailed in Appendix S1 and S2. Note
that in our approach we estimated the distribution of time from
infection diagnosis for individuals who were newly infected in a
specific year (and not for individuals who were diagnosed in a
specific year), and throughout the article, we used the term dis-
tribution of time from infection diagnosis to refer to this distri-
bution. Briefly, our model relies on the principle that trends in
newly diagnosed HIV cases reflect both trends in HIV incidence
and the distribution of times from infection to diagnosis. Thus,
the former can be used to estimate the latter. However, due to
the lack of identifiability in distinguishing changes in HIV inci-
dence from changes in distribution of times from infection to
diagnosis, some estimates may be unreliable, unless extra infor-
mation on one of the two indicators to estimate (HIV incidence
or the distribution of times from infection diagnosis) is incorpo-
rated into the model. In our approach, we used data on the clin-
ical status at diagnosis to bring information on the distribution
of time from infection to diagnosis. We considered three clinical
status: PHI, AIDS, neither PHI nor AIDS. Individuals diagnosed
with PHI were assumed to have short time intervals from infec-
tion to diagnosis (3 months in median) while individuals diag-
nosed with AIDS were assumed to have longer time intervals,
and depending on the natural AIDS incubation time (10 years
in median). Individuals diagnosed without PHI or AIDS were
assigned with intermediate, but unknown, time intervals,
depending on two parameters representing uptake of routine
testing and onset of HIV symptoms that occur towards the end
of the incubation period. Values for these two parameters
together with HIV incidence were then simultaneously esti-
mated by fitting the back-calculation model to the observed
numbers of new HIV diagnoses stratified by clinical stage.
2.3 | Number of undiagnosed HIV infections
To estimate the number of individuals living with undiagnosed
HIV, we used estimates of HIV incidence and distribution of
times from infection to diagnosis. The method has been
described elsewhere [26] and is detailed in Appendix S3 in
SM. Briefly, the estimated number of new HIV infections was
projected forward according to the distribution of times from
infection to diagnosis to obtain estimates of the number of
individuals living with undiagnosed HIV infection in a given
year. Specifically, from the number of newly HIV-infected indi-
viduals at each point in time, we estimated those who were
still undiagnosed in a given year, using the cumulative proba-
bilities of not being diagnosed with HIV over time; these
Marty L et al. Journal of the International AIDS Society 2018, 21:e25100
http://onlinelibrary.wiley.com/doi/10.1002/jia2.25100/full | https://doi.org/10.1002/jia2.25100
2
probabilities were calculated from the distributions of time
between infection and diagnosis.
2.4 | Producing estimates at the national and
subnational level and by population
We first used national data on newly diagnosed HIV cases
from 2004 to 2014 (Figure S1A) to obtain estimates of the
three epidemiological indicators at the national level. Then, we
used data on newly diagnosed HIV cases from 2004 to 2014
of each region of France to produce regional estimates; in
2014, there were 27 regions in France, including 21 mainland
regions, Corsica and five overseas regions: Guyane in South
America (also known as French Guyana), Guadeloupe and
Martinique in the Caribbean, and Reunion and Mayotte in the
Indian Ocean. We also produced, at the national level and in
four selected regions, estimates by sex, HIV exposure group
and country of birth. The exposure group is determined based
on what individuals declare as the probable mode of HIV
acquisition when diagnosed with HIV. If more than one mode
is reported, the case is classified in the exposure category
listed first in the following hierarchy: man who have sex with
men (MSM), person who injects drugs (PWID) and heterosex-
ual. For the country of birth, we split individuals between
those born in France and those born abroad, and among those
born broad we also produced estimates for individuals born in
Sub-Saharan Africa (SSA). The four regions, namely Guyane,
Ile-de-France (the Paris region), Provence-Alpes-Côte d’Azur
and Centre, were selected to illustrate contrasted situations
regarding the burden of HIV epidemic and the populations
most affected by HIV (Figure S1B). We produced mean and
95% confidence intervals (CI) using a bootstrap procedure
(see Appendix S4 in SM). Note that in the results section, we
present our estimates for the year 2014 for incidence and
undiagnosed HIV prevalence, while for the time to diagnosis,
we chose to present the distribution for individuals infected
between 2011 and 2014, and not only in 2014, because the
time to diagnosis can greatly vary from year to year, but also
variation may not be pertinent to inform testing strategies.
The denominators used for rate calculations at the national
and subnational level were based on population size (aged 18
to 64) estimates in 2014 produced by the French National
Institute of Statistics and Economic Studies [29], which also
provides estimates according to the country of birth, and esti-
mates from the latest national surveys on sexual behaviour
[30] and drug use [31]. Note that for the denominator of the
incidence rate we subtracted the HIV prevalence [12] from
the population size. We defined MSM as men who had at
least one sexual intercourse with another man in the past
12 months and PWID as people who injected drugs in the
past 12 months. More details are given in SM on population
size estimates, calculation of rates and statistical comparisons
(see Appendix S5 to S7).
3 | RESULTS
In 2014, in France, an estimated 6607 new infections
occurred, corresponding to an incidence rate of 1.7 per
10,000 (Table 1). There were an estimated 24,197 individuals
living with undiagnosed HIV, corresponding to an undiagnosed
prevalence rate of 6.1 per 10,000 (Table 1). The median time
from infection to diagnosis for individuals infected from 2011
to 2014 was 3.3 years (interquartile range (IQR): 1.2 to 5.7).
3.1 | Geographical heterogeneity
Forty-two percent of the estimated new infections (2757 out
of 6607) occurred among people living in Ile-de-France (Fig-
ure 1A).
Two regions of the south-east of France, Provence-Alpes-
Côte d’Azur and Rhône-Alpes, accounted for 14% of the esti-
mated new infections (respectively 625 and 318 new infec-
tions). It is in these three regions that were living 56% of the
undiagnosed individuals (Figure 1B): Ile-de-France region
(42%, 10,117 out of 24,197), Provence-Alpes-Côte d’Azur (8%)
and Rhône-Alpes (6%). Relating these numbers to the size of
the population living in each region, we found that seven
regions had at least one rate higher than national level (p-
values < 0.0001, red-coloured regions on Figure 1C and D).
Guyane had rates (per 10,000 inhabitants) of incidence and
undiagnosed prevalence around ten times higher (respectively
16.8 and 65.6), followed by Guadeloupe with rates three times
higher (respectively 5.4 and 20.5), Ile-de-France and Mar-
tinique with rates around two times higher (respectively 3.7
and 13.4 for Ile-de-France, 4.3 and 14.0 for Martinique), and
Provence-Alpes-Côte-d’Azur (respectively 2.2 and 6.8) and
Languedoc-Roussillon (respectively 2.0 and 6.3) with rates sig-
nificantly higher than the national level (p-value < 0.0001).
Centre had slightly but significantly higher incidence rate than
the national level (1.9; p-value < 0.0001, red-coloured region
on Figure 1C). Time from infection to diagnosis for individuals
infected from 2011 to 2014 remained long and not signifi-
cantly different than national level in most regions (yellow-
coloured regions on Figure 1E), and significantly different in
two regions (blue-coloured regions on Figure 1E) with median
lower or equal than the national level in Alsace (2.2 years) and
Auvergne (3.3 years), (p-values < 0.0001).
3.2 | Population heterogeneity
At the national level, while MSM, heterosexuals and PWID
represented, respectively, 0.8%, 98.9% and 0.3% of the gen-
eral population, in 2014, 44% of the new HIV infections
(2938 out of 6607) and 38% of undiagnosed infections (9181
out of 24,197) occurred among MSM, respectively, 54% and
61% among heterosexuals, and 1% and 1% among PWID,
respectively (Table 1). Among MSM, 22% of the new infec-
tions or undiagnosed infections occurred among born-abroad
MSM. Among PWID, about 33% of the new infections and
43% undiagnosed infections occurred among born-abroad
PWID. Regarding born-abroad heterosexuals, among women
more than 70% of the new infections or undiagnosed infec-
tions occurred among SSA-born women and among men
around 70% of the new infections or undiagnosed infections
occurred among SSA-born men. When considering rates (per
10,000) of incidence and undiagnosed prevalence, the most
affected populations were born-abroad MSM (with respective
rates of 181.8 and 480.2), MSM born in France (respectively
104.5 and 269.6), born-abroad PWID (respectively 23.6 and
107.7) and SSA-born heterosexual women (respectively 25.1
and 91.5) and men (respectively 19.2 and 77.6). The rates of
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Figure 1. Subnational estimates for France. (A) Number of new HIV infections in 2014; (B) number of undiagnosed HIV infections in 2014;
(C) number of new HIV infections per 10,000 inhabitants (aged 18 to 64 years old) in 2014; (D) number of undiagnosed HIV infections per
10,000 inhabitants (aged 18 to 64 years old) in 2014; (E) median time between infection and diagnosis (in years) for individuals infected
between 2011 and 2014. *We could not provide estimates for Corse and Mayotte because of incomplete surveillance data. In (A) and (B),
yellow-coloured regions correspond to regions with numbers close to average number of new infections individuals in A (i.e. 6607/27245)
and undiagnosed HIV individuals in B (i.e. 24,197/27  896), and in (E) to regions with distributions of times from infection to diagnosis not
statistically different than the national-level distribution; Estimated national rates were 1.7 per 10,000 (95% CI: 1.5 to 1.8) for HIV incidence,
6.1 per 10,000 (95% CI: 5.7 to 6.6) for undiagnosed HIV infections and the national-level median time between infection and diagnosis was
3.3 years (interquartile range: 1.2 to 5.7). In (A–D), light blue (respectively dark blue) coloured regions correspond to regions with numbers
or rates more than twice lower (respectively less than twice lower) than average numbers or national rates, while dark red (respectively light
red) coloured regions correspond to regions with numbers or rates more than nine times higher (respectively less than nine times higher)
than average numbers or national rates. In (E), light blue-coloured regions correspond to regions with distribution of times from infection to
diagnosis statistically different than the national-level distribution, with values for the median lower than or equal to that of the national
level. The maps were produced using the package maptools in R 3.2.4 [39].
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HIV incidence and undiagnosed HIV prevalence were higher
than the national rates for each of these populations (p-
values < 0.0001): 108- and 78-fold, 62- and 44-fold, 14- and
18-fold, 15- and 15-fold, 11- and 13-fold respectively. Among
individuals infected between 2011 and 2014, heterosexual
men and PWID born in France had longer time to diagnosis
than MSM and heterosexual women (medians of >4 years ver-
sus ≤3.2 years) but it was only statistically significant for
heterosexual men (p-values < 0.0001 for all two-by-two com-
parisons).
3.3 | Geographical and population heterogeneity
To illustrate existing heterogeneity in how populations are
affected by HIV according to the geographic area, we chose
to focus on four selected regions.
In Ile-de-France, rates of incidence and undiagnosed preva-
lence were, respectively, 195.9 and 450.7 for born-abroad
MSM, 151.2 and 344.7 for MSM born in France, 28.6 and
98.2 for SSA-born heterosexual women, 19.6 and 88.7 for
SSA-born heterosexual men, and 17.9 and 54.4 for PWID
(Table 2). Heterosexual men and PWID had longer time from
HIV infection to diagnosis than MSM and heterosexual women
(medians of ≥4 years vs. ≤3 years) but it was only statistically
significant for heterosexual men (p-values < 0.05 for two-by-
two comparisons except heterosexual men born in France
against heterosexual women born in France).
In Provence-Alpes-Côte d’Azur, born-abroad MSM and
MSM born in France had by far the highest rates (per
10,000) of incidence (respectively 57.8 and 102.1) and undiag-
nosed prevalence (respectively 169.4 and 223.9) compared to
other groups (p-values < 0.0001, Table 2). Heterosexual men
tended to have longer times from HIV infection to diagnosis
than other groups (medians of >4 years vs. ≤3 years for the
other groups, p-values < 0.05 for all two-by-two comparisons
for heterosexual men born in France against MSM born in
France and born-abroad heterosexual men against born-
abroad heterosexual women).
In the region Centre, we could only produce estimates by
sex, and for two groups, MSM and born-abroad heterosexual
women that represented, respectively, 37% and 27% of the
new HIV diagnoses (Figure S1B). Rates (per 10,000) of inci-
dence and undiagnosed prevalence were, respectively, 244.6
and 600.1 for MSM and 27.0 and 128.8 for SSA-born hetero-
sexual women (Table 2).
In Guyane, we could only produce estimates by sex, and for
two groups, born-abroad heterosexual women and men that
represented, respectively, 40% and 30% of the new HIV diag-
noses (Figure S1B). Rates (per 10,000) of incidence and undi-
agnosed prevalence were, respectively, 23.9 and 94.8 for
born-abroad heterosexual women and 26.0 and 109.4 for
born-abroad heterosexual men (Table 2). Time from infection
to diagnosis tended to be longer among born-abroad hetero-
sexual men than born-abroad heterosexual women (median of
4.1 years vs. 3.0, p-value = 0.4636).
4 | DISCUSSION
In France, substantial heterogeneity exists in HIV incidence,
undiagnosed HIV prevalence and time from infection to
diagnosis across locations and populations. These features of
the French HIV epidemics need to be accounted for to
improve prevention and care in France. To the best of our
knowledge, this is the first study quantifying within-country
geographical and population heterogeneity for these three key
epidemiological indicators.
HIV affects all regions of France, but four regions (three
overseas and one mainland) were more affected than others.
By far, the most impacted region was Guyane, located in
South America, with HIV incidence and undiagnosed HIV
prevalence rates around 10 times higher than national rates.
Next, it was Guadeloupe, an island in the Caribbean, followed
by Martinique, another island in the Caribbean, and Ile-de-
France, which includes Paris, the biggest city of France, with
rates two to three times higher than national level. Remark-
ably, more than 40% of the new and undiagnosed HIV infec-
tions occurred among people living in Ile-de-France, while only
19% of the French population (aged 18 to 64) lives in this
region. HIV affects all populations but five populations were
more affected than others. By far, the most affected popula-
tions were born-abroad MSM and MSM born in France, with
undiagnosed HIV prevalence and HIV incidence rates 44- to
108-fold higher than the national level. Then, it was born-
abroad persons who inject drugs and SSA-born heterosexuals
(men and women), with rates 11- to 18-fold higher than the
national level.
The populations most affected by HIV differed from one
region to another and in regions that were apparently less
affected than the four aforementioned, some populations were
as impacted by HIV as those living in the most impacted area. In
Ile-de-France, the most impacted populations were MSM,
whether born in France or abroad, followed by SSA-born
heterosexual women and men, and PWID. In Provence-Alpes-
Côte d’Azur, it was mainly MSM, whether born in France or
abroad, while in Centre it was both MSM and SSA-born hetero-
sexual women. In these last two regions, incidence and undiag-
nosed HIV prevalence rates for MSM and SSA-born
heterosexual women were as high as those estimated for these
populations in Ile-de-France. In Guyane, the most impacted pop-
ulations were heterosexual men and women born in Haiti or in
the Americas. A common feature for all regions was that times
from infection to diagnosis for individuals remained long for all
populations, and especially for heterosexual men, whether born
in France or abroad, who had, or tended to have, longer time
intervals from infection to diagnosis.
The main strength of our approach is that it only requires
data on newly diagnosed HIV cases. Our approach can be
applied to any country collecting data on the annual number of
newly diagnosed HIV cases as well as the clinical status at diag-
nosis, exposure group and country of birth, which includes most
high-income countries [32]. Several things were done to check
the internal and external validity of our results (see
Appendix S8 of the SM), nevertheless, our results are subject to
a number of limitations affecting surveillance data and data
used to determine the size of populations. As surveillance data
on new HIV cases were not exhaustive, they were adjusted for
missing entries, reporting delay and under-reporting [28].
Potential inaccurate adjustment could affect our estimates. Fur-
thermore, as French surveillance system on newly diagnosed
HIV cases was paper-based until recently, it was labour inten-
sive and time-consuming to collect data, and thus, it generated
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gaps in data availability, which prevented producing more timely
estimates. Our findings reflect then the epidemiological situa-
tion in 2014, and thus attitudes towards HIV testing and pre-
vention until that year. If these attitudes have changed since
2014, for example with use of PrEP, which was made available
in France in 2016, it could have altered estimates for HIV infec-
tion, and to a lower extent estimates for the undiagnosed preva-
lence. One could also argue that universal treatment, which was
implemented in France at the end of 2013, had influenced beha-
viours towards HIV testing, yet in the past, no major changes in
HIV testing behaviours were observed when treatment eligibil-
ity guidelines were changed [33]. Gap in data availability is not
an issue specific to France, but rather a global issue. Addressing
this issue, and improving the timeliness of surveillance data
availability for analysis and dissemination, for instance develop-
ing a national-based electronic surveillance system—this was
done in France in 2016—should be a priority, because real-time
epidemiological estimates can be a powerful tool to design,
monitor and evaluate interventions aiming to prevent HIV infec-
tion and/or reduce time to diagnosis.
In addition, estimates of the size of some populations, such as
MSM and PWID, remain uncertain because they are imprecise at
the subnational level and rely on definitions that may be too
restrictive. We defined MSM and PWID based on sexual activity
or drug use over the last twelve months. More inclusive defini-
tions, based on sexual activity or drug use over the last two or
five years, would have led to higher population sizes and lower
rates. Moreover, national surveys [30,31] provided estimates of
the prevalence of MSM and PWID at the national and subna-
tional level, but not according to the country of birth. We then
assumed that the prevalence of MSM and PWID was similar
among individuals born in France and those born abroad, but it
remains unclear whether and how this assumption could have
biased our results. Moreover, to produce regional estimates, we
used the region of residence at diagnosis.While, it seems reason-
able to assume that the region of residence at diagnosis brings
some information on where individuals were living before being
diagnosed, thus on where individuals were living with undiag-
nosed HIV infection, the region of residence at diagnosis does
not bring any information on where individuals acquired HIV.
Some individuals, especially among those born abroad, may have
acquired HIV infections outside France. A recent study con-
ducted among SSA migrants living in Ile-de-France showed that
from 51% to 65% of them acquired HIV before migrating in
France [34].Thus, we probably overestimated the number of new
HIV infections that occurred in France, and thus HIV incidence
rates, especially among born-abroad individuals, and in regions,
where the proportion of born-abroad individuals among newHIV
cases is high. Finally, our back-calculation model accounts for
some, and maybe not all, changes in test-seeking behaviours that
occurred over time. These changes are essentially driven by the
time-varying proportions of individuals diagnosed with PHI (see
Appendix S2 in SM). By assuming that, for individuals diagnosed
without PHI or AIDS, uptakes of HIV testing due to routine medi-
cal examination or onset of HIV symptoms that occur towards
the end of the incubation period were constant over the 2004 to
2014 period, we may have failed to appreciate all the changes in
test-seeking behaviours. However, annual number of HIV tests
performed in France remained fairly stable over the 2004 to
2014 period [33], suggesting that no major changes in test-seek-
ing behaviours occurred over this period.
Our results show that in France, a high number of new and
undiagnosed HIV infections (>40%) are concentrated in a delim-
ited geographical area, namely the region Ile-de-France. This
offers the opportunity to intensify prevention and testing pro-
grammes in this area to eventually impact HIV transmission in
this area, and possibly elsewhere in France. Indeed, recent phylo-
genetic studies concluded that the region Ile-de-France was the
major hub of dissemination in France [35,36], and that among
clusters of primary HIV infections involving patients living in not
contiguous regions 70% involved one patient living in Paris area
[37]. This suggests that reducing HIV transmission in Ile-de-
France could indirectly reduce HIV transmission in other regions
of France. Our findings also revealed that, for all HIV exposure
groups (i.e. MSM, heterosexuals and PWID), born-abroad individ-
uals account for a significant fraction of the number of new and
undiagnosed HIV infections. Moreover, when considering rates,
born-abroad populations are among the most affected by HIV.
This calls for tailored HIV prevention and testing interventions
towards these individuals and shows the importance of produc-
ing sub-population estimates. Moreover, we found that in geo-
graphical areas that appear less impacted by HIV, some
populations (e.g. born-abroad MSM, SSA-born women) can be as
impacted by HIV than those living in the most impacted area,
thus our findings also clearly invite to implement and target HIV
prevention and testing programmes towards specific populations
in each region of France, based on key epidemiological indicators,
such as HIV incidence, undiagnosed HIV prevalence and time
from infection to diagnosis. Finally, we found that times from
infection to diagnosis remained long in all regions and for all pop-
ulations, and especially for heterosexual men. Time to diagnosis
could be an interesting surrogate metric to monitor access to
cART in France, and probably in many other settings. Indeed, we
previously showed that, in France, HIV diagnosis remained the
main gap in the continuum of HIV care and thus the duration
between HIV infection and cART initiation was highly dependent
on the time to HIV diagnostic [12]. As a consequence, monitoring
the time to diagnosis and implementing interventions aiming at
reducing this time will be essential to accelerate cART initiation,
on which depends the success of treatment as prevention.
Similar geographical and population heterogeneity are likely
to occur in other settings and need to be investigated. Unravel-
ling these heterogeneity is key to impact HIV transmission at
the population level, by intensifying intervention programmes
in most affected geographical areas, and reduce individual-level
risk of HIV acquisition and time from infection to diagnosis,
by targeting affected populations in each geographical area.
Without a granular view of the HIV epidemics within countries,
it will not be possible to close gaps in HIV prevention and care
continuums, and thus end the HIV and AIDS epidemics. In this
study, we used surveillance data on newly diagnosed HIV cases,
which are mainly available in most high-income countries. In
other settings, there also exists surveillance systems collecting
data on uptake of antiretroviral therapy, currently underused,
for which back-calculation models can also be developed to
derive subnational estimates [38].
5 | CONCLUSIONS
Our study clearly shows that the HIV epidemic in France is
diverse. Risks of HIV acquisition, of undiagnosed HIV infections
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and time to HIV diagnosis are not uniformly distributed across
geographical areas and populations. This highlights not only the
need to design, adapt and/or implement subnational tailored
HIV prevention and testing programmes based on key epidemio-
logical indicators, such as HIV incidence, undiagnosed HIV preva-
lence and time from infection to diagnosis, in France, but also in
other settings where similar heterogeneity is likely to exist.
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